Effect of Roxadustat versus erythropoietin (EPO) for treating anemia in patients with diabetic kidney disease: a retrospective cohort study

BACKGROUND: Renal anemia of diabetic kidney disease (DKD) shows higher incidence rate, earlier onset and higher severity than other chronic kidney disease (CKD). Roxadustat, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor, improves CKD anemia. This retrospective cohort study evaluates...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, Liu, Yulu, Huang, Ying, Zhao, Yuee, Wei, Cong, Yang, Kexin, Li, Xiaohui, Zhang, Shumin, Wang, Wenpeng, Liu, Yu, Liu, Fuyou, Sun, Lin, Xiao, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761136/
https://www.ncbi.nlm.nih.gov/pubmed/36544686
http://dx.doi.org/10.21037/atm-22-4344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761136/
https://www.ncbi.nlm.nih.gov/pubmed/36544686
http://dx.doi.org/10.21037/atm-22-4344

Ejemplares similares